It has been a month when @siamosolocani 1st flagged this variant. Later, I started tracking it. We are still amid an ongoing surge, it’s time to take a stock of the situation: what we do know, what we don’t 1/
1-XBB.1.16 has succeeded in creating a new, significant surge in India after a gap of >6 months. A feat that even BA.5, BQ.1 & XBB.1.5 failed to achieve! 2/
2-XBB.1.16 definitely has got a growth advantage & more fitter than other circulating XBBs & has even replaced some other similar sublineages like XBB.1.5 & XBB.1.9 3/ @vinodscaria
3-XBB.1.16 is definitely not a more pathogenic variant than other Omicron’s progenies
4-This variant is still evolving, adding few more mutations. But not all new mutations are beneficial to the virus (i.e. E180V). 4/
5-The chances of XBB.1.16 leading a new, significant wave (i.e. the 4th wave) akin to Jan’ 22 BA.2 wave are remote 5/ @JPWeiland
6-The new surge in cases is yet to peak in India. According to @JPWeiland India is more than 2 weeks from peak cases. 6/
And, now let’s see what we still don’t know:
1-How big this new surge would be?
2-What are the key factors responsible for making XBB.1.16 a more fitter variant than its contemporaries? Higher immune evasion?
Higher infectiousness, i.e. higher ACE2 binding? 7/
We know XBB.1.5 & XBB.1.16 have almost similar Spike barring a few Spike mutations. However, above study suggests that mutations in the non-Spike region may be responsible for increased viral growth of XBB.1.16 10/
The above mentioned study & some early work done by @StuartTruvile in NSW, Australia points that XBB.1.16 is not more immune evasive than XBB.1.5. @StuartTurville calls it “super similar to XBB.1.5 in neut evasion”. 11/
Now, If it's not immune evasion, is the growth advantage is because of stronger ACE2 binding then?
No, in fact, the entry into cells is similar as with Omicrons including XBB.1.5. @StuartTurville has shown this 👇 12/
Most evolutionary biologists now agree to believe that the increased fitness is mainly due to changes at non-Spike region of this variant.
Acc to @LongDesertTrain ORF1a:L3829F is probably the key mute responsible for its advantage over XBB.1.9 13/
As per @SolidEvidence mutation in NSP6 of ORF1ab may be behind this higher fitness 14/
Now, most experts believe the extra mutations at ORF9b & ORF1a are responsible to give “teeth” to this variant.
ORF9b is thought to be involved with suppressing interferon response, so they might make the virus slightly fitter by counteracting the innate immune system. 15/
We still don’t know whether XBB.1.16 will become a global thing replacing the existing dominant variant XBB.1.5. However, all the indications point it will. This is the current projection by @JPWeiland for the US (an update on the CDC graph) 16/
• • •
Missing some Tweet in this thread? You can try to
force a refresh
A plethora of respiratory viruses, including SARS-CoV-2, strategically manipulate the host's splicing machinery to circumvent antiviral responses. 1/
What is RNA splicing? ....a form of RNA processing in which a newly made precursor messenger RNA (pre-mRNA) transcript is transformed into a mature messenger RNA (mRNA). During splicing, introns (non-coding regions) are removed, & exons (coding regions) are joined together 2/
According to a new study, SARS-CoV-2 exploits the host splicing machinery to bolster viral replication & subvert the immune response by selectively upregulating unproductive splicing isoforms from antigen presentation & antiviral response genes. 3/
When is the Indian Covid surge driven by XBB.1.16 going to peak?
Y’day India reported >7500 cases. Early trends point the tally would def cross 8500 today. However, there is a lot of speculations on when the current peak of the surge would peak. Let’s look for the answers 1/
There are three different views:
1-According to @JPWeiland as far as weekly growth is concerned, it is already peaked. But the outbreak is still growing & the positivity rate is at the highest since Jan’21 BA.2 peak! 2/
2-As per the @MoHFW_INDIA’s ‘unusual’ claim, the COVID in India is moving towards the endemic stage. They expect the cases to rise for the next 10-12 days, and will gradually come down to become endemic 3/
I remember during my ppts for IAP’s ‘Mission Cowin’ I used to refer ORF8 an accessory protein of SARS2 that mediates immune evasion through down-regulating MHC-I 2/
ORF8 gained recognition in SARS-CoV-2 pathogenesis due to its hypervariability, secretory property, and unique structure.
Some recent papers even today describe its pivotal roles in both viral replication & immune evasion. 3/
A new study isolated two human antibodies, 12-16 & 12-19, which neutralise all SARS-CoV-2 variants tested (including XBB.1.5.). They also blocked infection in hamsters w/ BA.1 intranasally.
The fig characterises in vitro & in vivo potency and breadth of these two mAbs 1/
Structural analyses revealed both Abs targeted a conserved epitope located at the interface between NTD & subdomain 1, revealing a previously unrecognized site of vulnerability on SARS2 spike.
Antibodies 12-16 and 12-19 target a quaternary epitope between SD1 and NTD 2/
Interestingly, these Abs prevent viral receptor engagement by locking the RBD of spike in down conformation, revealing a novel mechanism of virus neutralization for non-RBD Abs. Antibody binding is incompatible w/ RBD-up state, suggesting antibody is “locked” in a down state. 3/
Just wondering why most experts are not bothered by the rising Covid infections. They are only obsessed w/ only deaths & hospitalisations. This is a wrong narrative. If we are not able to prevent infections, we are playing in the hands of this virus 1/
You see the basic aim of any virus is to survive and transmit from one person to other. And for that it needs to infect a cell. The more the infections, the more opportunities for the virus to propagate, multiply & mutate inside the human body. 2/
Till it strikes a ‘perfect’ combination of mutations in a perfect milieu (an immunocompromised host). That may provide the virus to make more copies of itself (higher infectivity) or evade barriers to its multiplication (means immunity). 3/
The current SARS2 landscape is dominated by XBB sublineages, descendants of Omicron BA.2 variant. Though there may be several reasons for the higher fitness of these subvariants, but an important reason could be the binding of microRNAs to viral genome 1/
In somatic cells, microRNAs (miRNAs) bind to the genomes of RNA viruses and influence their translation and replication. 2/
A new study demonstrates that a significant number of miRNA binding sites is located in the NSP4 region of the SARS2 genome, and the human intestinal miRNAs exert evolutionary pressure on this region. 3/